Cargando…
Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
Cardiovascular diseases (CVD) are a global health concern, affecting millions of patients worldwide and being the leading cause of global morbidity and mortality, thus creating a major public health concern. Sodium/glucose cotransporter 2 (SGLT2) inhibitors have emerged as a promising class of medic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377079/ https://www.ncbi.nlm.nih.gov/pubmed/37509724 http://dx.doi.org/10.3390/biomedicines11072085 |
_version_ | 1785079427768516608 |
---|---|
author | Frąk, Weronika Hajdys, Joanna Radzioch, Ewa Szlagor, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata |
author_facet | Frąk, Weronika Hajdys, Joanna Radzioch, Ewa Szlagor, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata |
author_sort | Frąk, Weronika |
collection | PubMed |
description | Cardiovascular diseases (CVD) are a global health concern, affecting millions of patients worldwide and being the leading cause of global morbidity and mortality, thus creating a major public health concern. Sodium/glucose cotransporter 2 (SGLT2) inhibitors have emerged as a promising class of medications for managing CVD. Initially developed as antihyperglycemic agents for treating type 2 diabetes, these drugs have demonstrated significant cardiovascular benefits beyond glycemic control. In our paper, we discuss the role of empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and the relatively recently approved bexagliflozin, the class of SGLT-2 inhibitors, as potential therapeutic targets for cardiovascular diseases. All mentioned SGLT-2 inhibitors have demonstrated significant cardiovascular benefits and renal protection in clinical trials, in patients with or without type 2 diabetes. These novel therapeutic approaches aim to develop more effective treatments that improve patient outcomes and reduce the burden of these conditions. However, the major scientific achievements of recent years and the many new discoveries and mechanisms still require careful attention and additional studies. |
format | Online Article Text |
id | pubmed-10377079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103770792023-07-29 Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors Frąk, Weronika Hajdys, Joanna Radzioch, Ewa Szlagor, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata Biomedicines Review Cardiovascular diseases (CVD) are a global health concern, affecting millions of patients worldwide and being the leading cause of global morbidity and mortality, thus creating a major public health concern. Sodium/glucose cotransporter 2 (SGLT2) inhibitors have emerged as a promising class of medications for managing CVD. Initially developed as antihyperglycemic agents for treating type 2 diabetes, these drugs have demonstrated significant cardiovascular benefits beyond glycemic control. In our paper, we discuss the role of empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and the relatively recently approved bexagliflozin, the class of SGLT-2 inhibitors, as potential therapeutic targets for cardiovascular diseases. All mentioned SGLT-2 inhibitors have demonstrated significant cardiovascular benefits and renal protection in clinical trials, in patients with or without type 2 diabetes. These novel therapeutic approaches aim to develop more effective treatments that improve patient outcomes and reduce the burden of these conditions. However, the major scientific achievements of recent years and the many new discoveries and mechanisms still require careful attention and additional studies. MDPI 2023-07-24 /pmc/articles/PMC10377079/ /pubmed/37509724 http://dx.doi.org/10.3390/biomedicines11072085 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Frąk, Weronika Hajdys, Joanna Radzioch, Ewa Szlagor, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors |
title | Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors |
title_full | Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors |
title_fullStr | Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors |
title_full_unstemmed | Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors |
title_short | Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors |
title_sort | cardiovascular diseases: therapeutic potential of sglt-2 inhibitors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377079/ https://www.ncbi.nlm.nih.gov/pubmed/37509724 http://dx.doi.org/10.3390/biomedicines11072085 |
work_keys_str_mv | AT frakweronika cardiovasculardiseasestherapeuticpotentialofsglt2inhibitors AT hajdysjoanna cardiovasculardiseasestherapeuticpotentialofsglt2inhibitors AT radziochewa cardiovasculardiseasestherapeuticpotentialofsglt2inhibitors AT szlagormagdalena cardiovasculardiseasestherapeuticpotentialofsglt2inhibitors AT młynarskaewelina cardiovasculardiseasestherapeuticpotentialofsglt2inhibitors AT ryszjacek cardiovasculardiseasestherapeuticpotentialofsglt2inhibitors AT franczykbeata cardiovasculardiseasestherapeuticpotentialofsglt2inhibitors |